Endoscopic resection is the established treatment for early gastric cancer in selected patients with negligible risk of lymph node metastasis ('absolute indication'). Based on clinical observations and large pathological databases, expanding indications for endoscopic resection beyond absolute indication has been tried in Japan and Korea. However, controversies exist regarding the safety of treating early gastric cancer beyond absolute indication in terms of pathological evaluation of the resected specimen, definition of expanded indication, discrepancy between pre-endoscopic resection and post-endoscopic resection diagnoses of gastric neoplasm, and the best strategy for cases with non-curative resection. In this brief review, current evidence and clinical experience regarding issues of endoscopic resection beyond absolute indication will be summarized.
Introduction
Gastric cancer is one of the most common malignancies in Korea and many other countries. 1 Because screening endoscopy or barium gastrography is quite commonly performed in Korea 2 and Japan, 3 the proportion of early gastric cancer (EGC) at diagnosis is rapidly increasing. At the same time, instruments and techniques of endoscopic resection (ER) for EGC have been developed. ER is an established treatment modality for EGC with negligible risk of lymph node (LN) metastasis.
The original technique of ER was endoscopic mucosal resection (EMR), and the treatment outcome of EMR has been reported to be acceptable. [4] [5] [6] [7] [8] However, tumors larger than 2 cm in diameter are difficult to cut in one piece using EMR; therefore, the rate of local recurrence is somewhat high. In the era of EMR, the indications for endoscopic treatment were rather limited ('guideline indication' in Japan and 'absolute indication' [AI] in Korea). To overcome the limitations of EMR, the technique of endoscopic submucosal dissection (ESD) was developed in the late 1990s. The major advantage of ESD is that larger tumors can be removed endoscopically in one piece; therefore, the rate of local recurrence can be minimized. 9 Using the ESD technique for EGC patients with a low risk of LN metastasis, identified from a large surgical database, 10 many patients with EGC beyond AI have been treated using ESD. However, data on the long-term outcome is still limited.
Controversies exist regarding the safety of treating EGC beyond AI. Some issues related to optimal evaluation of the endoscopically resected EGC specimen are unsolved. No consensus has been reached on the definition of expanded indication (EI), and the ambiguity of the histological category of 'differentiated type'
and 'undifferentiated type' is worrisome in countries outside Japan. Additionally, discrepancies between pre-ER and post-ER diagnoses of gastric neoplasm have not been addressed adequately. by hematoxylin-eosin (H&E) staining. 12 The incidence of LN micrometastasis ranges from 10% to 36% in patients with pN0 gastric cancer. 12 Maehara et al. 13 In a study of 300 gastric cancer patients with pT1N0 tumor, Morgagni et al. 15 reported no significant differences in the 10-year overall survival rates among patients with or without LN micrometastasis. In contrast, Cao et al., 16 in a study of 160 gastric cancer patients with pT1N0 tumors, reported that LN micrometastasis was one of the independent prognostic factors in pN0 EGC patients. In this context, caution is needed to expand the indications for ER for EGC based on the surgical database of LN assessments by conventional HE staining. Therefore, the feasibility of ER for EI-EGC needs to be determined from outcome data.
Evaluation of submucosal invasion depth and lymphovascular emboli
One of the most important factors in the evaluation of endoscopically resected EGC is the depth of invasion. In mucosal cancers, the determination of invasion depth does not influence the clinical management plan. In submucosal cancer, however, depth of invasion is very important because surgery is usually recommended for cases with submucosal invasion greater than 500 mm. The thickness of the submucosa is variable, and many differences occur between specimens obtained from ER versus surgery. Cho et al. 17 demonstrated that the thickness of the submucosa significantly changed by being stretched before pinning it. Therefore, the handling process for ER specimens should be standardized, and objective measuring methods for submucosal invasion, complementing depth of tumor invasion, would make current submucosal invasion criterion more reliable.
In contrast to the low risk of LN metastasis reported by Gotoda et al. 10 and Hirasawa et al., 18 a significant LN metastasis rate (15%) was shown in minute submucosal cancers without lymphovascular invasion and measuring ≤3 cm in size. 19 If this discrepancy stems from the differences between Korean and Japanese pathologic criteria or methods, a criterion of submucosal invasion less than 500 mm should be challenged, and methods need to be standardized.
Moreover, this cut-off value (500 mm) was not obtained from ER specimens but from surgically resected gastric specimens.
The presence of lymphovascular emboli is one of the most 
Histological heterogeneity
To expand the indications for ER for submucosal invading EGC, the histological heterogeneity of gastric cancer is an important issue to be addressed. In a retrospective study comparing the clinicopathologic features of node-positive (n=35) and nodenegative (n=221) submucosal invading differentiated gastric cancers, histological heterogeneity was an independent risk factor for LN metastasis (odds ratio 3.88, 95% CI 1.60~9.38, P=0.0026). 22 Hanaoka et al. 23 
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In a recent study by Park et al., 42 the en bloc complete resection rate was lower in EI-EGC than in AI-EGC (83.2% vs. 89.1%, respectively, P=0.013). In cases of EGC with undifferentiated type histology, the curative resection rate seems to drop more (63.9%). 35 Noncurative resection after ER for EGC can be attributed to local recurrence or distant metastasis. Accordingly, it is important to establish the best strategy when curative resection is not achieved after ER in expanding indications for ER for EGC. Ryu et al. 43 presented data from 43 patients who underwent surgery after ER.
The surgical specimens showed residual cancer in 17 patients 
Outcome of Endoscopic Resection for Expanded Indication Early Gastric Cancer 1. Immediate technical outcome
In a retrospective study of EGC that fulfilled EI, en bloc resection was achieved in 94.9% (559/589), and 550 of 581 lesions (94.7%) were deemed to have undergone curative resection. 41 Perforation rate was higher in EI-EGC than in AI-EGC (6.3% vs.
2.0%, P＜0.05). Ahn et al. 25 Although these results could support the contention that experienced operators can achieve excellent short-term outcomes in the treatment of lesions that are technically more challenging, it is true that the short-term outcomes of EI-EGC were slightly worse compared to those of AI-EGC. Technical invasiveness appears to increase procedure time and the risk of complications.
Longterm clinical outcome
Favorable outcomes of ER have been reported in patients meeting EI for ER for EGC. 49 In Japan, Isomoto et al. 41 and Gotoda et al. 50 compared outcomes of ESD for EGC between AI and EI.
They reported no significant difference in the overall survival rates between AI-and EI-EGC. In Korean retrospective studies by Choi et al. 51 and Ahn et al., 25 the overall and disease-specific survival rates did not differ between AI-and EI-EGC. Lee et al. 52 and Park et al. 42 also reported similar disease-free survival rates between AIand EI-EGC. However, these studies did not have long follow-up periods, with median follow-up ranging from 26 to 44.1 months.
Recently, Kosaka et al. 53 presented the long-term outcomes of ESD for EGC in 438 patients who were followed for at least 5 years after treatment, although follow-up of more than half of the patients was based on a questionnaire survey. In their study, the 5-year survival rate was 83.1%, and no significant differences were seen between AI and EI. However, given few reports on the long-term outcomes of ER for EI-EGC, confirmation of more long-term outcomes under EI is warranted for establishing appropriate indications for ER for EGC.
Conclusions
Expanding indications for ER for EGC based on the surgical database needs to be carefully approached. The clinical significance of LN micrometastasis remains to be elucidated, and differences between specimens obtained from ER and surgery should be considered. To expand the range of ER for EGC, further efforts are needed to make ESD easier and safer, which could be achieved through technological advances, and the best strategy needs to be established for noncurative resection after ER. Surgery seems like a reasonable approach in cases at high risk for LN metastasis, and endoscopic treatment could be considered another method in cases at low risk for LN metastasis, particularly with only lateral margin positivity. Standardization of the pathologic diagnosis and handling process of ER specimens is also necessary for more reliable ER for EGC under EI. In cases of EGC with undifferentiated type histology, ESD needs to be considered for tumors smaller than 2 cm, and when ESD is carried out, adequate safety margins should be achieved. However, as 'differentiated and undifferentiated' is highly confusing, it would be better to avoid using these terms.
Considering significant discrepancies between pre-and posttreatment diagnoses of EGC, applying EI for selecting ESD for EGC could be risky. Finally, given few reports on the long-term outcomes of ER for EGC in EI, confirmation of more longterm outcomes under EI is warranted for establishing appropriate indications for ER for EGC.
